Galectin Therapeutics Inc. Warrants (GALTW)

[biotech2010]

Good day for GALT, 2 up days in a row.

For uncensored, honest conversation about GALT visit http://galt.freeforums.net/

[biotech2010]

Institutions won't believe any of it-Baker Brothers, the largest private fund that focuses on biotechs, purchased 500,000 shares on the open market in the past 8 months, including just under 400,000 during Q1, 2014.

There is a video from CNBC that discusses the FDA Fast Track program-every drug given Fast Track designation that came up for review in 2013 was approved (there were I believe 37 of them)-GALT is going to get an approval at some point in the future, it's just a matter of how broad a range of fibrosis it will be approved for.

[Darwinian]

I wonder though, will people believe what they are told by AF and his kind or the data?

[Darwinian]

Certainly seems to have an air of desperation about it...

[biotech2010]

And then another hatchet job by Feuerstein less than 2 hours later, they must be really afraid of tomorrow's report...

[biotech2010]

Another hatchet job on GALT today and 200K shares traded in 10 minutes.

The only thing I can surmise is that those with short positions are very, very concerned, there can be no other reason. If they were so convinced that GALT is a scam, why not just let the stock run higher and short it on the way up?

[biotech2010]

It's always interesting to see how manipulators like Adam Feuerstein can throw garbage out publicly without any fear of recrimination.

He single handedly dropped GALT $2 in 10 minutes by doing that on Twitter this afternoon.

I don't care very much since, at end of the day, GALT will succeed on its data and the efficacy of GR-MD-02 or the next generation drug but it would be very easy to be upset by his antics.

I won't post his Twitter feed or respond but he has made accusations today about the lack of a clinical endpoint in their trial that are complete bs-the current trial is a PHASE 1, there is no clinical endpoint to discuss since Phase 1's are, by definition, safety-related.

Feuerstein is a disgrace, period, end of discussion.

[biotech2010]

I didn't expect the run to be this strong today, hopefully it continues...

[Darwinian]

I'm almost green again. Let's see if it holds after results...or even before.

Hope so. Starting to think I made the right choice again.

Volume is crazy today and we still have Monday before results are due.

[biotech2010]

Market likes this announcement today, GALT up 13.5%, GALTW up 17%

[biotech2010]

Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis

http://ih.advfn.com/p.php?pid=nmona&article=63031552

You never know how the market will react to trial results but the most interesting part of this announcement is the reference to the use of Fibroscan in analyzing the data-if GALT didn't think the results were promising this would not have been in the press release (nor the reference to its use in a Phase 2 trial).

I've had this stock for over 5 years and have complete confidence in both the management team and the drug, we'll have to see how the market reacts to the results on Tuesday for the short term but long term they continue to be on course for a multi-billion dollar market cap company, probably at the conclusion of the Phase 2 trial for GR-MD-02.

[biotech2010]

I think the only thing that moves this stock is the Phase 1 Cohort 2 trial results next week.

If you look at the other developmental biotechs, there seems to be a market cap range for them depending on where they are in a trial and how large the potential market for the drug.

I would think that GALT would have a market cap in the range of $1B when it announces a Phase 2 based on the success of Phase 1, that puts the stock at about $40 (in line with analyst estimates) early next year.

I'm fine with that, there are lots of variables in all of this but my confidence in the GALT management team and the eventual success of their lead drug has never been higher.

You won't see me posting on the other GALT board, I have no interest in interacting with someone who has absolutely no knowledge of the company while constantly bragging about his incorrect predictions.

[Darwinian]

Looks like you were right. The announcement of the first patient dosed in the joint melanoma trial is great news but perhaps not the huge catalyst some have been waiting for, namely the cohort 2 results for NASH. Regardless, it's good to see you are still posting in regard to GALT/GALTW.

Looking forward to the next bit of news!

[biotech2010]

GALT up strongly today on bounce off 200 day MA but big run starting at 1PM

Pure speculation but stocks don't run on Friday afternoon without news unless there is something pending and it has leaked, possibly new trial results coming very soon.

[biotech2010]

Nice day for GALT, up 5%; GALTW up 8.94%.

Phase 1 Cohort 2 results are due in 2-3 weeks, should be an interesting data release...

[biotech2010]

GALTW is an excellent way to leverage an investment in GALT.

The basics are simple:
-GALTW has a strike price of $5.63
-GALTW expires in early 2017
-GALTW trades on NASDAQ in the same manner as GALT although trading volume is typically much lower than GALT

GALT current trades at $13.40, GALTW about $8.30-this means there is only a $0.53 premium on GALTW.

If GALT goes to $20, it will be about a 50% increase in share price; with the same move, GALTW will increase to $14.37, that is over 75%.

with a GALT move to $30 (125% increase), GALTW will increase to $24.37, almost a 200% increase.

I have held GALTW exclusively since the reverse split in March, 2012.